Joseph P. Lyssikatos Sells 847 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph P. Lyssikatos sold 847 shares of Enliven Therapeutics stock in a transaction on Friday, October 18th. The shares were sold at an average price of $30.00, for a total value of $25,410.00. Following the completion of the transaction, the insider now owns 1,015,188 shares of the company’s stock, valued at approximately $30,455,640. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Enliven Therapeutics Price Performance

ELVN opened at $28.98 on Friday. The firm has a market capitalization of $1.36 billion, a P/E ratio of -15.02 and a beta of 1.10. Enliven Therapeutics, Inc. has a one year low of $9.80 and a one year high of $30.03. The company has a fifty day moving average price of $24.62 and a 200-day moving average price of $22.93.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Tuesday, August 13th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.17. On average, analysts expect that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $37.00 target price on shares of Enliven Therapeutics in a report on Tuesday, October 1st.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ELVN. Janus Henderson Group PLC lifted its position in Enliven Therapeutics by 74.8% during the first quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock valued at $12,604,000 after purchasing an additional 305,397 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Enliven Therapeutics by 49.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 114,109 shares of the company’s stock valued at $2,667,000 after buying an additional 37,632 shares in the last quarter. First Turn Management LLC bought a new stake in shares of Enliven Therapeutics during the 2nd quarter worth $9,657,000. American Century Companies Inc. grew its position in Enliven Therapeutics by 44.7% in the second quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock worth $646,000 after acquiring an additional 8,540 shares in the last quarter. Finally, The Manufacturers Life Insurance Company bought a new position in Enliven Therapeutics in the second quarter valued at $322,000. 95.08% of the stock is currently owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.